International Vaccine Institute

501C3 Nonprofit Organization Information

  •   Get Unlimited Access to 990 Returns
  •   Get Unlimited Access to Financial Data
  •   Download in PDF format
Name & address International Vaccine Institute
Seoul 08826
Republic Of Korea, 00000-0000
EIN / Tax ID31-1621592
Classification501(c)(3)Charitable Organization
DeductibilityContributions are not deductible

International Vaccine Institute is a 501(c)(3) charitable nonprofit in Republic Of Korea (EIN 31-1621592). It has been tax-exempt since February 1999, and contributions to it are not tax-deductible. Its Form 990 for tax year 2024 reports total revenue of $68,966,984 and net assets of $94,592,624. TaxExemptWorld has Form 990s on file for 15 tax years (2009–2024). The IRS classifies its activity as Research Institutes and/or Public Policy Analysis (NTEE Q053).

LatestForm 990 summary · Tax year 2024

Form 990 · Tax period ending Dec 2024 · Filed Nov 15, 2025 · From the IRS e-file data

Total revenue$68,966,984-29% vs prior year
Total expenses$74,250,925-4% vs prior year
Net assets, end of year$94,592,624-5% vs prior year
Spent on programs80%of total expenses

Where the money goes

Programs 80%Management & general 20%Fundraising <1%

Dollar amounts for every revenue and expense line are in the full 990 report.

At a glance

Exempt status501(c)(3)
Formed1997
Employees260
Volunteers21
Voting board members20 (19 independent)
Websitewww.ivi.int

Mission (as filed): TO DISCOVER, DEVELOP AND DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR GLOBAL PUBLIC HEALTH. ITS VISION IS DEVELOPING COUNTRIES FREE OF SUFFERING FROM INFECTIOUS DISEASE.

Programs (as filed)

THE PHASE II COMPONENT OF THE STUDY IS COMPLETED, AND THE INTERIM CLINICAL STUDY REPORT (CSR) FROM PHASE II (PARTS A AND B) IS AVAILABLE. BASED ON ADDITIONAL TESTING RESULTS OF DAYS 28 AND 56 OF PHASE 2 SUBGROUP SAMPLES, DATA FROM NHP PASSIVE TRANSFER STUDY, AND SAFETY DATA, A FINAL DECISION ON THE OPTIMAL DOSE FOR PART C WAS MADE, AND 40 UG WAS SELECTED. A CONSORTIUM CONSENSUS JUSTIFICATION MEMO OF FINAL DOSE SELECTION IS COMPLETED. PROTOCOL AMENDMENT V 5.0 CONTAINING THIS NEW INFORMATION WAS APPROVED BY LOCAL ECS AND NRAS. VIRTUAL PI MEETINGS WITH ALL SITES TO UPDATE PROGRAM STATUS AND PROJ…

Share of program spending
4%

BPCOV2 PROJECT - 2024 SUMMARY OF ACTIVITIES (REFERENCE YEAR 2024) IN 2024, THE BPCOV2 PROJECT ADVANCED PRE-CLINICAL DEVELOPMENT OF A NEXT-GENERATION PAN-CORONAVIRUS MRNA VACCINE PLATFORM SUPPORTED BY CEPI. PROJECT PARTNERS (UPENN, UNC, UC DAVIS, CHULA VRC, AND IVI) FOCUSED ON MRNA CONSTRUCT DESIGN AND PRODUCTION. MULTIPLE MRNA CONSTRUCTS WERE PRODUCED AND TESTED, INCLUDING SPIKE VARIANTS, CHIMERIC CONSTRUCTS, AND VLP PLATFORMS, FORMULATED WITH SM-102 TO ENABLE PLATFORM COMPARISON.

Share of program spending
3%

VAT0008 IS A PIVOTAL MULTI-COUNTRY PHASE 3, MULTI-STAGE, MODIFIED DOUBLE-BLIND AND MULTI-ARM STUDY WHERE EFFICACY, SAFETY AND IMMUNOGENICITY OF TWO SARS-COV-2 ADJUVANTED RECOMBINANT PROTEIN VACCINES (MONOVALENT AND BIVALENT) WERE TESTED AS PRIMARY SERIES AND MONOVALENT BOOSTER DOSE AS AN EXTENSION. IVI LED THE EFFORT IN NEPAL TO CONDUCT THE CLINICAL TRIAL INCLUDING CONDUCTING THE LOCAL DSMB MEETING. THE PRIMARY SERIES STUDY WAS INITIATED IN JULY 2021. THE FIRST SUBJECT FOR THE PRIMARY SERIES WAS ENROLLED IN SEPTEMBER 2021. THE CROSSOVER/BOOSTER PHASE STARTED IN JANUARY 2023. THE LAST SUBJECT …

Share of program spending
3%

ALL OTHER PROGRAMS

Share of program spending
91%

Officers & directors

17Director / Board of Trustee
1Associate Director General
1Associate Director General Epidemiology
1Chairperson / Board of Trustee
1Chief Operating Officer
1Deputy Director General, Clinical Assessment
1Deputy Director General, Clinical, Assessment
1Deputy Director General, Epidemiology
1Deputy Director General, Global Affairs
1Deputy Director General, Government Relations
34 people listed on the return 20 voting board members, 19 independent58 paid over $100,00010 with no reported pay
Names, titles, hours and pay for all 34 are in the full 990 report and data download.

Governance

Conflict of interest policyYes
Whistleblower policyYes
Document retention policyYes
Process for setting CEO payYes
Form 990 given to board before filingNo
Board meeting minutes keptYes
Audit committeeYes
Family or business ties among officersNo
Financial statements auditedYes
Political campaign activityNo
Material diversion of assetsNo

Public charity (509(a)(1), 170(b)(1)(A)(vi)) · 53.8% public support

Prepared by TaxExemptWorld from IRS Form 990 e-file data (object ID 202543199349303654). Not an official IRS form.

  • Executive officer name & phoneAvailable with membership or data download
  • In care of nameAvailable with membership or data download
  • TaxonomyResearch Institutes and/or Public Policy Analysis
  • Filing requirementForm 990 - (all other) or 990EZ return
  • AffiliationThis organization is an independent organization or an independent auxiliary (i.e., not affiliated with a National, Regional, or Geographic grouping of organizations).
  • Foundation typeOrganization which receives a substantial part of its support from a governmental unit or the general public
  • Tax period12/2024

Form 990s on file

990 Summary PDFs 12 years · built from the IRS e-file data
202420232022201820172016201520142013201220112010
990 IRS Filing PDFs 12 years · scanned returns released by the IRS
202120192018201720162015201420132012201120102009
Download the full report All available information, plus 990 summaries and 990 IRS Filing PDFs for all 15 tax years.

In the full 990 report for International Vaccine Institute

  • Names, titles, hours and pay for all 34 officers & directors, including 58 paid over $100,000
  • Every revenue source and expense line in dollars, with expenses split by program, management & fundraising
  • Full balance sheet: assets, liabilities and net assets at the start and end of the year
  • Dollars spent on each program
  • Revenue and asset history by year
  • Form 990s for 15 tax years, 2009–2024: 12 TaxExemptWorld summaries and 12 IRS PDFs